Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200614521> ?p ?o ?g. }
- W4200614521 endingPage "263" @default.
- W4200614521 startingPage "243" @default.
- W4200614521 abstract "Risk of herpes zoster (HZ) is increased with Janus kinase inhibitor use. We evaluated clinical study data relating to HZ management in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) receiving tofacitinib.This post hoc analysis included data from 21 RA and 3 PsA clinical studies; data were pooled for tofacitinib doses. Outcomes of HZ events (serious and non-serious) and tofacitinib treatment changes were evaluated in response to first and second HZ events. Median time to resolution was stratified by dermatomal involvement, history of HZ prior to tofacitinib, changes to tofacitinib treatment, anti-viral and corticosteroid use, and tofacitinib dose.Seven hundred eighty-three (11.1%, N = 7061) patients with RA experienced ≥ 1 HZ event, 63 (8.0%) of whom had ≥ 2 HZ events. In patients with PsA, 36 (4.6%, N = 783) experienced ≥ 1 HZ event, 1 (2.8%) of whom had ≥ 2 HZ events. For most HZ events, tofacitinib treatment was unchanged or temporarily discontinued. The majority of patients received anti-viral treatment, most within 3 days of onset. Post-herpetic neuralgia developed in 6.9% and 3.2% of patients with RA with first and second events, respectively, and in 2.8% of patients with PsA with a first event. Most first and second events resolved (RA: 97.6% and 96.8%, respectively; PsA: 94.4% and 100%, respectively). Median time to resolution was 22.0 days for first and 15.0 days for second events for RA and 20.5 days for first and 11.0 days for second events (n = 1) for PsA. Time to resolution of first events for RA and PsA was generally numerically shorter for patients with single dermatomal HZ, history of HZ, or anti-viral use versus those without.Among patients receiving tofacitinib, recurrent events were more common in patients with RA versus PsA; HZ duration was shorter for repeat events.NCT01262118, NCT01484561, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT02147587, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02187055, NCT00413699, NCT00661661, NCT01877668, NCT01882439, NCT01976364.Patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) have weakened immune responses and are more likely to get herpes zoster (HZ; also known as shingles) infections compared with the general population. Patients who receive treatments for RA or PsA that have an effect on their immune system are more likely to get HZ. Here, we assessed how common HZ was in patients with RA or PsA who were given tofacitinib during clinical trials, the management of these infections, and how this affected the course of the infection. Approximately 1 in 10 patients with RA and 1 in 20 patients with PsA had HZ. Of those patients who had HZ, 1 in 12 with RA and 1 in 36 with PsA were infected again at a later point. A small number of patients also had long-lasting pain after HZ infection. When patients had a HZ infection, most either continued treatment with tofacitinib or paused treatment for a period of time. Pausing or continuing treatment did not appear to affect how long the infection lasted or whether patients had another infection. Most patients received treatment for HZ infection, and patients who were treated had shorter infections. In most patients, infections cleared up and were more likely to clear up more quickly when patients had HZ previously." @default.
- W4200614521 created "2021-12-31" @default.
- W4200614521 creator A5000754711 @default.
- W4200614521 creator A5006070255 @default.
- W4200614521 creator A5024958150 @default.
- W4200614521 creator A5030754645 @default.
- W4200614521 creator A5034591782 @default.
- W4200614521 creator A5070084831 @default.
- W4200614521 creator A5074629207 @default.
- W4200614521 creator A5076851275 @default.
- W4200614521 date "2021-12-06" @default.
- W4200614521 modified "2023-10-01" @default.
- W4200614521 title "Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment" @default.
- W4200614521 cites W1572054273 @default.
- W4200614521 cites W1974321634 @default.
- W4200614521 cites W1990105300 @default.
- W4200614521 cites W2010207831 @default.
- W4200614521 cites W2014330392 @default.
- W4200614521 cites W2035320881 @default.
- W4200614521 cites W2038992287 @default.
- W4200614521 cites W2040947756 @default.
- W4200614521 cites W2069302785 @default.
- W4200614521 cites W2069871920 @default.
- W4200614521 cites W2087531046 @default.
- W4200614521 cites W2097302763 @default.
- W4200614521 cites W2101217991 @default.
- W4200614521 cites W2129603347 @default.
- W4200614521 cites W2129948300 @default.
- W4200614521 cites W2131041950 @default.
- W4200614521 cites W2138609584 @default.
- W4200614521 cites W2149447280 @default.
- W4200614521 cites W2153414586 @default.
- W4200614521 cites W2163184895 @default.
- W4200614521 cites W2164858045 @default.
- W4200614521 cites W2254470680 @default.
- W4200614521 cites W2265836205 @default.
- W4200614521 cites W2297608701 @default.
- W4200614521 cites W2329705186 @default.
- W4200614521 cites W2338472944 @default.
- W4200614521 cites W2343866616 @default.
- W4200614521 cites W2400185681 @default.
- W4200614521 cites W2400874359 @default.
- W4200614521 cites W2413887177 @default.
- W4200614521 cites W2482912927 @default.
- W4200614521 cites W2514570228 @default.
- W4200614521 cites W2559774515 @default.
- W4200614521 cites W2617172995 @default.
- W4200614521 cites W2626892937 @default.
- W4200614521 cites W2734390848 @default.
- W4200614521 cites W2748091531 @default.
- W4200614521 cites W2749941863 @default.
- W4200614521 cites W2766717228 @default.
- W4200614521 cites W2766846920 @default.
- W4200614521 cites W2916179527 @default.
- W4200614521 cites W2926455583 @default.
- W4200614521 cites W2937719347 @default.
- W4200614521 cites W2949232069 @default.
- W4200614521 cites W2953281250 @default.
- W4200614521 cites W3003460520 @default.
- W4200614521 cites W3006153447 @default.
- W4200614521 cites W3018387634 @default.
- W4200614521 cites W3039282954 @default.
- W4200614521 cites W3042129498 @default.
- W4200614521 cites W3043603104 @default.
- W4200614521 cites W3048528702 @default.
- W4200614521 cites W3094882380 @default.
- W4200614521 cites W3097773625 @default.
- W4200614521 cites W3124820301 @default.
- W4200614521 cites W3139210094 @default.
- W4200614521 doi "https://doi.org/10.1007/s40744-021-00390-0" @default.
- W4200614521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34870800" @default.
- W4200614521 hasPublicationYear "2021" @default.
- W4200614521 type Work @default.
- W4200614521 citedByCount "5" @default.
- W4200614521 countsByYear W42006145212022 @default.
- W4200614521 countsByYear W42006145212023 @default.
- W4200614521 crossrefType "journal-article" @default.
- W4200614521 hasAuthorship W4200614521A5000754711 @default.
- W4200614521 hasAuthorship W4200614521A5006070255 @default.
- W4200614521 hasAuthorship W4200614521A5024958150 @default.
- W4200614521 hasAuthorship W4200614521A5030754645 @default.
- W4200614521 hasAuthorship W4200614521A5034591782 @default.
- W4200614521 hasAuthorship W4200614521A5070084831 @default.
- W4200614521 hasAuthorship W4200614521A5074629207 @default.
- W4200614521 hasAuthorship W4200614521A5076851275 @default.
- W4200614521 hasBestOaLocation W42006145211 @default.
- W4200614521 hasConcept C126322002 @default.
- W4200614521 hasConcept C141071460 @default.
- W4200614521 hasConcept C16005928 @default.
- W4200614521 hasConcept C2776233030 @default.
- W4200614521 hasConcept C2776260265 @default.
- W4200614521 hasConcept C2777077863 @default.
- W4200614521 hasConcept C2777575956 @default.
- W4200614521 hasConcept C2778886723 @default.
- W4200614521 hasConcept C71924100 @default.
- W4200614521 hasConcept C90924648 @default.
- W4200614521 hasConceptScore W4200614521C126322002 @default.
- W4200614521 hasConceptScore W4200614521C141071460 @default.